Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 4/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2371269 | 1.00 | PREP (0.67) | PREPCHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL27101241 | 1.00 | PREP (0.67) | PREPCHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL15934761 | 1.00 | PREP (0.67) | PREPCHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL903505 | 0.90 | PREP (0.68) | PREPCHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL18177046 | 0.90 | PREP (0.68) | PREPCHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL6504447 | 0.90 | PREP (0.68) | PREPCHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL22811006 | 0.90 | PREP (0.68) | PREPCHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL20689888 | 0.90 | PREP (0.68) | PREPCHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL21863336 | 0.90 | PREP (0.68) | PREPCHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL12294932 | 0.90 | PREP (0.68) | PREPCHRM2CHRM1CHRM3HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559487-B2 | Crosslinked optically active secondary amine derivative | Sumitomo Pharma Co., Ltd. (JP) | 2026-02-24 | — | — | US | disclosed |
| US-20250177395-A1 | OPTICALLY ACTIVE AZABICYCLO RING DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2025-06-05 | — | — | US | disclosed |
| US-12263167-B2 | Optically active azabicyclo ring derivative | Sumitomo Pharma Co., Ltd. (JP) | 2025-04-01 | — | — | US | disclosed |
| US-12139497-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-20240148727-A1 | OPTICALLY ACTIVE AZABICYCLO RING DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2024-05-09 | — | — | US | disclosed |
| US-11911381-B2 | Optically active azabicyclo ring derivative | Sumitomo Pharma Co., Ltd. (JP) | 2024-02-27 | — | — | US | disclosed |
| EP-3533797-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-12-20 | — | — | EP | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20130029969-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-31 | — | — | US | disclosed |
| EP-2540728-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2013-01-02 | — | — | EP | disclosed |
| WO-2012040923-A1 | TETRACYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| US-20110064698-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| EP-1737863-B1 | 2-CYANOPYRROLIDINECARBOXAMIDES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ASTELLAS PHARMA INC (JP) | 2008-12-31 | — | — | EP | disclosed |
| US-7186731-B2 | 2-cyanopyrrolidinecarboxamide compound | ASTELLAS PHARMA INC. (JP) | 2007-03-06 | — | — | US | disclosed |
| US-7179918-B2 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-20050137224-A1 | 2-Cyanopyrrolidinecarboxamide compound | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-23 | — | — | US | disclosed |
| US-5384322-A | Prolylendopeptidase inhibitors; Alzheimer*s disease; antidepressant and anxiolytic agents | ADIR ET COMPAGNIE (FR) | 1995-01-24 | — | — | US | disclosed |
| US-4965250-A | TETRAPEPTIDE; IMMUNE SYSTEM ACTIVATION | ADIR ET CIE (FR) | 1990-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, F12, F3 | PREP 292/4885CHRM2 2752/4885CHRM1 3197/4885 |
| US-12559487-B2 | Crosslinked optically active secondary amine derivative | MLLT3, MLLT1, FLI1 | PREP 4836/4885CHRM2 2396/4885CHRM1 1621/4885 |
| US-20130029969-A1 | HETEROCYCLIC COMPOUND | TP53, VHL, MGMT | PREP 802/4885CHRM2 4748/4885CHRM1 4277/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | PREP 330/4885CHRM2 3139/4885CHRM1 3516/4885 |
| US-20050137224-A1 | 2-Cyanopyrrolidinecarboxamide compound | DPP4, DPP3, DPP7 | PREP 91/4885CHRM2 149/4885CHRM1 274/4885 |
| US-11911381-B2 | Optically active azabicyclo ring derivative | MLLT3, MEN1, MLLT1 | PREP 4708/4885CHRM2 3961/4885CHRM1 2604/4885 |
| US-20240148727-A1 | OPTICALLY ACTIVE AZABICYCLO RING DERIVATIVE | MLLT3, MEN1, MLLT1 | PREP 4708/4885CHRM2 3961/4885CHRM1 2604/4885 |
| US-12263167-B2 | Optically active azabicyclo ring derivative | MLLT3, MEN1, MLLT1 | PREP 4708/4885CHRM2 3961/4885CHRM1 2604/4885 |
| US-20250177395-A1 | OPTICALLY ACTIVE AZABICYCLO RING DERIVATIVE | MLLT3, MLLT1, MEN1 | PREP 4698/4885CHRM2 4185/4885CHRM1 2960/4885 |
| US-20110064698-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | PREP 519/4885CHRM2 4835/4885CHRM1 4755/4885 |
| US-12139497-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | PREP 323/4885CHRM2 2731/4885CHRM1 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.